CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	At-The-Market Offering Program	Ordinary shares	Ordinary shares At-The-Market Offering Program	Preferred shares	Additional paid-in capital	Additional paid-in capital At-The-Market Offering Program	Accumulated deficit	Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2023			89,825,000
Beginning balance (in shares) at Dec. 31, 2023					5,194,000
Beginning balance at Dec. 31, 2023	$ 87,739		$ 898		$ 52	$ 855,452		$ (745,496)	$ (23,167)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(27,342)							(27,342)
Other comprehensive income (loss)	(589)								(589)
Issuance of common stock, net of issuance costs (in shares)				640,000
Issuance of common stock, net of issuance costs		$ 9,250		$ 6			$ 9,244
Amortization of deferred issuance costs	(3)					(3)
Conversion of preferred stock into ordinary shares (in shares)			5,194,000		(5,194,000)
Conversion of preferred stock into ordinary shares	0		$ 52		$ (52)
Exercise of stock options (in shares)			390,000
Exercise of stock options	3,356		$ 3			3,353
Employee share purchase plan share issuance (in shares)			48,000
Employee share purchase plan share issuance	584		$ 1			583
Share-based compensation expense	5,389					5,389
Ending balance (in shares) at Mar. 31, 2024			96,097,000
Ending balance (in shares) at Mar. 31, 2024					0
Ending balance at Mar. 31, 2024	78,384		$ 960		$ 0	874,018		(772,838)	(23,756)
Beginning balance (in shares) at Dec. 31, 2023			89,825,000
Beginning balance (in shares) at Dec. 31, 2023					5,194,000
Beginning balance at Dec. 31, 2023	87,739		$ 898		$ 52	855,452		(745,496)	(23,167)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(43,789)
Other comprehensive income (loss)	(635)
Ending balance (in shares) at Sep. 30, 2024			96,338,000
Ending balance (in shares) at Sep. 30, 2024					0
Ending balance at Sep. 30, 2024	74,663		$ 963		$ 0	886,787		(789,285)	(23,802)
Beginning balance (in shares) at Mar. 31, 2024			96,097,000
Beginning balance (in shares) at Mar. 31, 2024					0
Beginning balance at Mar. 31, 2024	78,384		$ 960		$ 0	874,018		(772,838)	(23,756)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(13,822)							(13,822)
Other comprehensive income (loss)	(459)								(459)
Exercise of stock options (in shares)			107,000
Exercise of stock options	723		$ 1			722
Share-based compensation expense	5,462					5,462
Ending balance (in shares) at Jun. 30, 2024			96,204,000
Ending balance (in shares) at Jun. 30, 2024					0
Ending balance at Jun. 30, 2024	70,288		$ 961		$ 0	880,202		(786,660)	(24,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(2,625)							(2,625)
Other comprehensive income (loss)	413								413
Exercise of stock options (in shares)			69,000
Exercise of stock options	400		$ 1			399
Employee share purchase plan share issuance (in shares)			65,000
Employee share purchase plan share issuance	777		$ 1			776
Share-based compensation expense	5,410					5,410
Ending balance (in shares) at Sep. 30, 2024			96,338,000
Ending balance (in shares) at Sep. 30, 2024					0
Ending balance at Sep. 30, 2024	$ 74,663		$ 963		$ 0	886,787		(789,285)	(23,802)
Beginning balance (in shares) at Dec. 31, 2024	96,518,000		96,518,000
Beginning balance (in shares) at Dec. 31, 2024	0				0
Beginning balance at Dec. 31, 2024	$ 73,848		$ 965		$ 0	891,791		(794,328)	(24,580)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(4,920)							(4,920)
Other comprehensive income (loss)	268								268
Exercise of stock options (in shares)			60,000
Exercise of stock options	282		$ 1			281
Vesting of restricted shares (in shares)			8,000
Employee share purchase plan share issuance (in shares)			46,000
Employee share purchase plan share issuance	409					408		1
Share-based compensation expense	4,183					4,183
Ending balance (in shares) at Mar. 31, 2025			96,632,000
Ending balance (in shares) at Mar. 31, 2025					0
Ending balance at Mar. 31, 2025	$ 74,070		$ 966		$ 0	896,663		(799,247)	(24,312)
Beginning balance (in shares) at Dec. 31, 2024	96,518,000		96,518,000
Beginning balance (in shares) at Dec. 31, 2024	0				0
Beginning balance at Dec. 31, 2024	$ 73,848		$ 965		$ 0	891,791		(794,328)	(24,580)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	4,765
Other comprehensive income (loss)	$ 1,004
Ending balance (in shares) at Sep. 30, 2025	97,235,000		97,235,000
Ending balance (in shares) at Sep. 30, 2025	0				0
Ending balance at Sep. 30, 2025	$ 98,225		$ 972		$ 0	910,391		(789,562)	(23,576)
Beginning balance (in shares) at Mar. 31, 2025			96,632,000
Beginning balance (in shares) at Mar. 31, 2025					0
Beginning balance at Mar. 31, 2025	74,070		$ 966		$ 0	896,663		(799,247)	(24,312)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	9,665							9,665
Other comprehensive income (loss)	666								666
Exercise of stock options (in shares)			145,000
Exercise of stock options	981		$ 1			980
Share-based compensation expense	5,327					5,327
Ending balance (in shares) at Jun. 30, 2025			96,777,000
Ending balance (in shares) at Jun. 30, 2025					0
Ending balance at Jun. 30, 2025	90,709		$ 967		$ 0	902,970		(789,582)	(23,646)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	20							20
Other comprehensive income (loss)	70								70
Exercise of stock options (in shares)			313,000
Exercise of stock options	1,957		$ 3			1,954
Vesting of restricted shares (in shares)			72,000
Vesting of restricted shares	0		$ 1			(1)
Employee share purchase plan share issuance (in shares)			73,000
Employee share purchase plan share issuance	550		$ 1			549
Share-based compensation expense	$ 4,919					4,919
Ending balance (in shares) at Sep. 30, 2025	97,235,000		97,235,000
Ending balance (in shares) at Sep. 30, 2025	0				0
Ending balance at Sep. 30, 2025	$ 98,225		$ 972		$ 0	$ 910,391		$ (789,562)	$ (23,576)

AVADEL PHARMACEUTICALS PLC 10-Q